Astellas signs on pluripotent stem cell partners at ExCellThera; Little Unicycive brings home $25M after floating a small IPO
Astellas has signed up on rights for a batch of pluripotent stem cells from Montreal-based ExCellThera, centering on the in vitro use of their …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
